Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02923739 · M.D. Anderson Cancer Center · PHASE2 · terminated · last registry update 2024-03-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated early by the Sponsor” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VEGFA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-13Also stopped (terminated): IVERIC bio, Inc., Avacincaptad Pegol + Avastin (NCT05571267)
- 2025-03-07Phase 3 first posted: 4D Molecular Therapeutics, 4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL) (NCT06864988)
- 2025-03-04Phase 3 first posted: Adverum Biotechnologies, Inc., Ixo-vec + Aflibercept (NCT06856577)
- 2025-02-26Phase 3 first posted: Hoffmann-La Roche, Ranibizumab (NCT06847542)
- 2025-02-24Results posted on the registry: Novartis Pharmaceuticals, Brolucizumab (NCT04774926)
- 2025-02-24Results posted on the registry: Wake Forest University Health Sciences, Aflibercept Ophthalmic (NCT04707625)
- 2025-02-24Also stopped (terminated): Wake Forest University Health Sciences, Aflibercept Ophthalmic (NCT04707625)
- 2025-02-14Results posted on the registry: Amgen, ABP 938 + Aflibercept (NCT05704725)
- 2025-02-05Results posted on the registry: John Hays, aflibercept + oxaliplatin (NCT01652196)
- 2025-01-27Results posted on the registry: Novartis Pharmaceuticals, Brolucizumab (NCT04679935)
- 2025-01-24Phase 3 first posted: Jaeb Center for Health Research, Faricimab (NCT06790784)
- 2024-12-30Results posted on the registry: Samsung Bioepis Co., Ltd., SB11 PFS (NCT06176963)
- 2024-12-10Results posted on the registry: Novartis Pharmaceuticals, Injection Brolucizumab (NCT05269966)
- 2024-12-09Results posted on the registry: Novartis Pharmaceuticals, Brolucizumab 6mg + Aflibercept 2 mg (NCT04047472)
- 2024-11-12Phase 3 first posted: EyePoint Pharmaceuticals, Inc., EYP-1901 + Aflibercept (2.0 mg) (NCT06683742)
- 2024-11-07Results posted on the registry: Novartis Pharmaceuticals, RTH258/Brolucizumab (NCT04264819)
- 2024-10-31Phase 3 first posted: EyePoint Pharmaceuticals, Inc., EYP-1901 + Aflibercept (2.0 mg) (NCT06668064)
- 2024-10-31Also stopped (terminated): Ophthotech Corporation, E10030 + bevacizumab or aflibercept (NCT01940887)
- 2024-10-30Results posted on the registry: Hoffmann-La Roche, Faricimab (NCT04432831)
- 2024-10-30Also stopped (terminated): Ophthotech Corporation, Fovista® + bevacizumab (NCT02387957)
- 2024-10-30Also stopped (terminated): Ophthotech Corporation, E10030 + ranibizumab (NCT01944839)
- 2024-10-30Also stopped (terminated): Ophthotech Corporation, E10030 + ranibizumab (NCT01940900)
- 2024-10-16Results posted on the registry: Bayer, Aflibercept(BAY86-5321, Eylea) (NCT05473715)
- 2024-10-16Also stopped (terminated): Bayer, Aflibercept(BAY86-5321, Eylea) (NCT05473715)
- 2024-10-15Also stopped (terminated): Tufts Medical Center, Aflibercept (NCT03396861)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision